Site-Specific Immunomodulator: A Novel Treatment for Crohn’s Disease

Site-Specific Immunomodulator: A Novel Treatment for Crohn’s Disease

We investigated the mechanism of action, safety, and efficacy of the Site-Specific Immunomodulator (SSI) QBECO, a novel immunotherapy for Crohn’s disease (CD). Using human monocytic THP-1 cells, we demonstrate that SSI QBECO (derived from the common colon bacteria E. coli) activates macrophages to a...

Full description

Bibliographic Details
Main Authors:	Brian Bressler, Kevin P. Bethel, Ralf Kleef, Sophie L. Reynolds, Simon Sutcliffe, David W. Mullins, Hal Gunn
Format:	Article
Language:	English
Published:	Hindawi Limited 2015-01-01
Series:	Gastroenterology Research and Practice
Online Access:	http://dx.doi.org/10.1155/2015/231243

Similar Items

Comparison of Concomitant Mesalamine and Immunomodulator Therapy and Immunomodulator Monotherapy for Crohn’s Disease
by: Min Seob Kwak, et al.
Published: (2018-01-01)

Novel Microbial-Based Immunotherapy Approach for Crohn's Disease
by: Simon Sutcliffe, et al.
Published: (2019-07-01)

The Role of Endoscopy in the Management of Postoperative Patients with Crohn’s Disease
by: Brian Bressler
Published: (2006-01-01)

Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia
by: Choon Jin Ooi, et al.
Published: (2019-07-01)

IMMUNOMODULATORS AND SPECIFIC PROPHYLAXIS OF INFECTIOUS DISEASES
by: N. D. Omel’chenko, et al.
Published: (2017-09-01)

Development of DC-specific lentiviral vectors: novel DC-targeting strategies for immunomodulation
by: Edelmann, Stephanie
Published: (2011)

Immunomodulation of Human Skin Cells by Extracts of the Scabies Mite, Sarcoptes scabiei
by: Mullins, Jeremi Stevan
Published: (2008)

Mycobacterium Avium Paratuberculosis and the Etiology of Crohn’s Disease: A Review of the Controversy from the Clinician’s Perspective
by: Greg Rosenfeld, et al.
Published: (2010-01-01)

The role of vedolizumab in patients with moderate-to-severe Crohn’s disease and ulcerative colitis
by: Neal Shahidi, et al.
Published: (2016-05-01)

IMMUNOMODULATORS IN SENESCENT MICE
by: McCormick, Kevin R.
Published: (1989)

Psychedelics and immunomodulation: Novel approaches and therapeutic opportunities
by: Attila eSzabo
Published: (2015-07-01)

Infliximab in the Treatment of Crohn’s Disease
by: Brian Feagan
Published: (2000-01-01)

Immunomodulation as a Novel Strategy for Prevention and Treatment of Bordetella spp. Infections
by: Monica C. Gestal, et al.
Published: (2019-12-01)

Microfilariae specific mechanisms of immunomodulation in a mouse model of filariasis
by: O'Connor, Richard Anthony
Published: (2001)

Mechanisms underlying immunomodulation of HIV-1-specific T-cell responses
by: Herasimtschuk, Anna Aracely
Published: (2012)

Specificities of presentation of Crohn’s disease in childhood
by: Bruna Karoline Pinheiro França Protásio, et al.

Crohn's Disease: Specific Concerns in the Elderly
by: Wei-Chen Lin, et al.
Published: (2016-09-01)

A Case of Adalimumab-Induced Pneumonitis in a 45-Year-Old Man with Crohn’s Disease
by: James D Reid, et al.
Published: (2011-01-01)

IMMUNOMODULATORS IN OPPORTUNISTIC INFECTIONS TREATMENT
by: A. P. Toptygina, et al.
Published: (2014-07-01)

Safety and immunomodulation evaluations on Chinese herbal novel formulas
by: Ann-Ru Wu, et al.
Published: (2006)

Immunotherapy and immunomodulation
Published: (2005-01-01)

Natural Immunomodulators
by: D. Ortuño-Sahagún, et al.
Published: (2017-01-01)

Immunomodulation of Epithelium
by: Mary H Perdue
Published: (1996-01-01)

Immunomodulation and immunotherapy
Published: (2005-01-01)

Immunosuppression and Immunomodulation
Published: (2023)

Immunopathology and Immunomodulation
Published: (2015)

Autoimmunity in Chagas' disease: immunomodulation of autoimmune and T. cruzi-specific immune responses
by: Luiz Vicente Rizzo, et al.
Published: (1988-11-01)

The plce of immunomodulators in the treatment of ENT organs
by: A. I. Kryukov, et al.
Published: (2016-12-01)

Early anti-TNF/immunomodulator therapy is associated with better long-term clinical outcomes in Asian patients with Crohn's disease with poor prognostic factors.
by: Eun Hye Oh, et al.
Published: (2017-01-01)

The Novel Effect of Immunomodulator-Glatiramer Acetate on Epileptogenesis and Epileptic Seizures
by: Ming-Chi Lai, et al.
Published: (2018-10-01)

Engineered Bovine Antibodies in the Development of Novel Therapeutics, Immunomodulators and Vaccines
by: Madhuri Koti, et al.
Published: (2014-05-01)

Immunomodulation in Cystic Fibrosis: Why and How?
by: Vincent D. Giacalone, et al.
Published: (2020-05-01)

Immunomodulation of Autoimmune Arthritis by Herbal CAM
by: Shivaprasad H. Venkatesha, et al.
Published: (2011-01-01)

Tolerogenic Immunomodulation by PEGylated Antigenic Peptides
by: Jennifer Pfeil, et al.
Published: (2020-10-01)

IMMUNONTROPHYCAL EFFECT TO USE OF THE IMMUNOMODULATOR AND PROBYOTIC OF IN COMPLEX CURENCE OF SPECIFIC SURGICAL INFECTIONS
by: R. Kh. Gismatov, et al.
Published: (2017-01-01)

Emerging Treatments for Crohn's Disease: Cells, Surgery, and Novel Therapeutics
by: Susanna Meade, et al.
Published: (2021-03-01)

EUDOGENOUS AND EXOGENOUS IMMUNOMODULATORS
by: Editorial article
Published: (2014-07-01)

EUDOGENOUS AND EXOGENOUS IMMUNOMODULATORS
by: Editorial article
Published: (2014-07-01)

EUDOGENOUS AND EXOGENOUS IMMUNOMODULATORS
by: Editorial article
Published: (2014-07-01)

EUDOGENOUS AND EXOGENOUS IMMUNOMODULATORS
by: Editorial article
Published: (2014-07-01)

Cannot write session to /tmp/vufind_sessions/sess_cpd40g68c2dnf4au7l1qpmoqg8